Menveo is a vaccine indicated for active immunization to prevent invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, Y, and W-135. Menveo is approved for use in persons 2 to 55 years of age. Menveo does not prevent N. meningitidis serogroup B infections.

You should not receive Menveo if you have had a severe allergic reaction to any ingredient of the vaccine, or if you have had a severe allergic reaction to a vaccine containing similar components as Menveo.

Side effects to Menveo include pain at the injection site, headache, muscle pain, fatigue, nausea, and fainting. Sometimes fainting is accompanied by falling with injury. Other side effects may occur.

Following vaccination with another US-licensed meningococcal conjugate vaccine, an evaluation of postmarketing adverse events suggested a potential for increased risk of Guillain-Barré Syndrome (GBS). There is not enough information to evaluate if a risk of GBS exists following administration of Menveo.

Tell your doctor if you are pregnant or planning to get pregnant.

Vaccination with Menveo may not protect all individuals.

For more information about Menveo, talk to your health-care professional.

Menveo.com has been developed by Novartis Vaccines as part of the company’s commitment to individual and public health.